Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences
CL Braal, EM Jongbloed, SM Wilting, RHJ Mathijssen… - Drugs, 2021 - Springer
The cyclin-dependent kinase (CDK) 4/6 inhibitors belong to a new class of drugs that
interrupt proliferation of malignant cells by inhibiting progression through the cell cycle …
interrupt proliferation of malignant cells by inhibiting progression through the cell cycle …
Therapeutic drug monitoring of oral targeted antineoplastic drugs
A Mueller-Schoell, SL Groenland… - European journal of …, 2021 - Springer
Purpose This review provides an overview of the current challenges in oral targeted
antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic drug …
antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic drug …
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)
A Bardia, SA Hurvitz, A DeMichele, AS Clark… - Clinical Cancer …, 2021 - AACR
Purpose: Standard-of-care treatment for metastatic hormone receptor–positive (HR+), HER2-
negative (HER2−) breast cancer includes endocrine therapy (ET) combined with a cyclin …
negative (HER2−) breast cancer includes endocrine therapy (ET) combined with a cyclin …
[HTML][HTML] Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study
SL Groenland, RAG Van Eerden, K Westerdijk… - Annals of …, 2022 - Elsevier
Background Oral targeted therapies show a high pharmacokinetic (PK) interpatient
variability. Even though exposure has been positively correlated with efficacy for many of …
variability. Even though exposure has been positively correlated with efficacy for many of …
The randomized AMBORA trial: Impact of pharmacological/pharmaceutical care on medication safety and patient-reported outcomes during treatment with new oral …
P Dürr, K Schlichtig, C Kelz, B Deutsch… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Oral anticancer drugs (eg, kinase inhibitors) play an important role in cancer
therapy. However, considerable challenges regarding medication safety of oral anticancer …
therapy. However, considerable challenges regarding medication safety of oral anticancer …
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment
SD Krens, G Lassche, FGA Jansman… - The Lancet …, 2019 - thelancet.com
Renal or hepatic impairment is a common comorbidity for patients with cancer either
because of the disease itself, toxicity of previous anticancer treatments, or because of other …
because of the disease itself, toxicity of previous anticancer treatments, or because of other …
Management of drug–drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs
RJ Brüggemann, R Verheggen, E Boerrigter… - The Lancet …, 2022 - thelancet.com
Over the past 10 years, the number of targeted therapies for haematological malignancies
has substantially increased, and many new drugs have entered the market. Many of these …
has substantially increased, and many new drugs have entered the market. Many of these …
Pharmacokinetics and pharmacodynamics of ruxolitinib: a review
TYJ Appeldoorn, THO Munnink, LM Morsink… - Clinical …, 2023 - Springer
Abstract Background and Objective Ruxolitinib is a tyrosine kinase inhibitor targeting the
Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways …
Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways …
Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib
SL Groenland, A Martínez-Chávez… - Clinical …, 2020 - Springer
Palbociclib, ribociclib, and abemaciclib are inhibitors of the cyclin-dependent kinases 4 and
6 approved for the treatment of locally advanced or metastatic breast cancer. In this review …
6 approved for the treatment of locally advanced or metastatic breast cancer. In this review …
Clinical pharmacokinetics and pharmacodynamics of dabrafenib
A Puszkiel, G Noé, A Bellesoeur, N Kramkimel… - Clinical …, 2019 - Springer
Dabrafenib is a potent and selective inhibitor of BRAF-mutant kinase that is approved, as
monotherapy or in combination with trametinib (mitogen-activated protein kinase (MAPK) …
monotherapy or in combination with trametinib (mitogen-activated protein kinase (MAPK) …